Mission Wealth Management, LP Vertex Pharmaceuticals Inc Transaction History

Mission Wealth Management, LP

$4.1 Billion
Q3 2024

A detailed history of Mission Wealth Management, LP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mission Wealth Management, LP holds 6,627 shares of VRTX stock, worth $3.33 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

6,627

Previous 5,812 14.02%

Holding current value

$3.33 Million

Previous $2.72 Million 13.14%

% of portfolio

0.08%

Previous 0.07%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$460.0 - $505.78 $374,900 - $412,210	815 Added 14.02%	6,627 $3.08 Million
Q2 2024 Aug 02, 2024	SELL	$392.81 - $485.53 $783,655 - $968,632	-1,995 Reduced 25.55%	5,812 $2.72 Million
Q1 2024 Apr 30, 2024	BUY	$407.69 - $446.08 $1.19 Million - $1.3 Million	2,914 Added 59.55%	7,807 $3.26 Million
Q4 2023 Feb 05, 2024	BUY	$343.0 - $410.68 $72,716 - $87,064	212 Added 4.53%	4,893 $1.99 Million
Q3 2023 Oct 23, 2023	BUY	$338.18 - $362.46 $23,672 - $25,372	70 Added 1.52%	4,681 $1.63 Million
Q2 2023 Aug 04, 2023	BUY	$314.42 - $351.91 $6,602 - $7,390	21 Added 0.46%	4,611 $1.62 Million
Q1 2023 Apr 07, 2023	BUY	$283.23 - $323.1 $18,126 - $20,678	64 Added 1.41%	4,590 $1.45 Million
Q4 2022 Feb 02, 2023	BUY	$285.76 - $321.48 $46,864 - $52,722	164 Added 3.76%	4,526 $1.31 Million
Q3 2022 Oct 12, 2022	BUY	$273.83 - $305.53 $26,287 - $29,330	96 Added 2.25%	4,362 $1.26 Million
Q2 2022 Jul 27, 2022	BUY	$234.96 - $292.55 $154,603 - $192,497	658 Added 18.24%	4,266 $1.2 Million
Q1 2022 Apr 25, 2022	BUY	$221.42 - $260.97 $108,938 - $128,397	492 Added 15.79%	3,608 $942,000
Q4 2021 Feb 11, 2022	SELL	$177.01 - $223.45 $9,735 - $12,289	-55 Reduced 1.73%	3,116 $684,000
Q3 2021 Nov 05, 2021	BUY	$181.39 - $202.99 $10,339 - $11,570	57 Added 1.83%	3,171 $575,000
Q2 2021 Aug 10, 2021	BUY	$187.49 - $221.1 $11,811 - $13,929	63 Added 2.06%	3,114 $628,000
Q1 2021 May 10, 2021	BUY	$207.02 - $241.31 $101,439 - $118,241	490 Added 19.13%	3,051 $656,000
Q4 2020 Jan 19, 2021	BUY	$207.01 - $276.09 $68,727 - $91,661	332 Added 14.89%	2,561 $605,000
Q3 2020 Oct 16, 2020	BUY	$255.65 - $303.1 $11,248 - $13,336	44 Added 2.01%	2,229 $607,000
Q2 2020 Aug 03, 2020	BUY	$225.48 - $295.8 $11,724 - $15,381	52 Added 2.44%	2,185 $634,000
Q1 2020 Apr 10, 2020	SELL	$199.77 - $247.81 $1,398 - $1,734	-7 Reduced 0.33%	2,133 $508,000
Q4 2019 Jan 21, 2020	BUY	$166.71 - $223.91 $20,838 - $27,988	125 Added 6.2%	2,140 $469,000
Q3 2019 Oct 16, 2019	SELL	$166.23 - $187.09 $76,299 - $85,874	-459 Reduced 18.55%	2,015 $341,000
Q2 2019 Aug 09, 2019	SELL	$164.61 - $190.37 $43,457 - $50,257	-264 Reduced 9.64%	2,474 $454,000
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $37,821 - $44,975	231 Added 9.21%	2,738 $504,000
Q4 2018 Feb 08, 2019	BUY	$151.91 - $192.21 $70,638 - $89,377	465 Added 22.77%	2,507 $415,000
Q2 2018 Aug 08, 2018	BUY	$145.72 - $169.96 $297,560 - $347,058	2,042 New	2,042 $347,000

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mission Wealth Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Mission Wealth Management, LP with notifications on news.

Account

Mission Wealth Management, LP Vertex Pharmaceuticals Inc Transaction History